Defence Therapeutics Common Stock

Defence Therapeutics (DTCFF) currently reports a common stock of $33M as of March 2026. That compares with $20M in the prior-year period — up 64.9% year over year. Use the charts on this page to explore Defence Therapeutics's common stock history and peer comparisons.

Defence Therapeutics's common stock increased from $20M to $33M — a 64.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Defence Therapeutics reported $33M in common stock as of March 2026. That compares with $20M in the prior-year period — up 64.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $33M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Defence Therapeutics, and consider following DTCFF for alerts when major investors trade the stock.

Defence Therapeutics is classified in the Healthcare sector. On common stock, it currently shows $33M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DTCFF with unrelated industries.